NCT Number: NCT05215574
Phase: Phase 1
Trial Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NGM Biopharmaceuticals, Inc|Merck Sharp & Dohme LLC
Acronym:
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives